REGENXBIO Inc. — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
FDA placed a clinical hold on RGX-121 (clemidsogene lanparvovec) for MPS II following discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study conducted 3–6 years prior. REGENXBIO does not expect to resubmit the BLA in the near term. The company is shifting focus to its Duchenne (RGX-202) and retinal disease (wet AMD) programs, with planned Duchenne BLA submission this quarter and wet AMD topline data in Q4 2026.
Why this rating
RGX-121 is a late-stage candidate; clinical hold halts a major pipeline asset. Relative to $385M market cap, this is a material setback. Duchenne and wet AMD near-term catalysts partially offset risk.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.